T. Rowe Price Associates disclosed a 5.3% stake in Nurix Therapeutics (NRIX). The investment was revealed in a Schedule 13G filing dated August 14, 2026.
The asset manager now beneficially owns 5,436,587 common shares. This position establishes T. Rowe Price as one of the company's largest shareholders.
Substantial investments by prominent firms often signal strong confidence in a company's future prospects.